<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559221</url>
  </required_header>
  <id_info>
    <org_study_id>C-007A</org_study_id>
    <nct_id>NCT00559221</nct_id>
  </id_info>
  <brief_title>FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML</brief_title>
  <official_title>Fludarabine and Cytarabine as Continuous Infusion Plus Idarubicin With Granulocyte-Colony Stimulating Factor (G-CSF) Priming for Patients Younger Than 60 Years With Resistant Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - To determine the feasibility of fludarabine and cytarabine as continuous infusion plus
      idarubicin with granulocyte-colony stimulating factor priming for patients with resistant
      acute myeloid leukemia other than acute promyelocytic leukemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      - The feasibility will be evaluated in terms of toxicities, complete remission rate, duration
      of complete remission, disease-free survival, and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission rate, duration of complete remission, toxicities</measure>
    <time_frame>06/2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival, overall survival</measure>
    <time_frame>06/2008</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLAG+IDA</intervention_name>
    <description>Fludarabine, cytarabine, G-CSF</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Failure to achieve CR after initial induction chemotherapy including standard dose
             cytarabine.

          -  Early relapse, occurring after a first CR lasting less than 12 months.

          -  Patients with multiple relapses will be included.

          -  Written informed consent must be given.

          -  15 and 60 years of age.

          -  2 or less by ECOG performance scale.

        Exclusion Criteria:

          -  acute promyelocytic leukemia

          -  pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hawk Kim, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ulsan Universtity Hospital, ROK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yae-Eun Jang, nurse</last_name>
    <phone>80-2-3010-7290</phone>
    <email>redpin75@paran.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yae-Eun , Jang</last_name>
      <phone>82-2-3010-7290</phone>
      <email>redpin75@paran.com</email>
    </contact>
    <investigator>
      <last_name>Hawk Kim, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>October 13, 2008</last_update_submitted>
  <last_update_submitted_qc>October 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

